AZN•benzinga•
SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $75
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 4, 2022 by benzinga